Cell Line Development Market size was over USD 5.44 billion in 2023 and is poised to cross USD 19 billion by 2036, witnessing more than 10.1% CAGR during the forecast period i.e., between 2024-2036. In the year 2024, the industry size of cell line development is evaluated at USD 5.88 billion. Further, the market generated a revenue of USD 4,588.5 Million in the year 2021. The growth of the market can be attributed to the growing demand for monoclonal antibodies. These antibodies help to stimulate immune system. Thus they are extensively used for treating cancer, migraines, and more. Further, rising burden of cancer is expected to boost the market growth. According to the World Health Organization, Cancer is the most common cause of death worldwide, accounting for almost 10 million fatalities in 2020, or nearly one in every six deaths.
Moreover, rising need for vaccine production is anticipated to fuel the growth of the cell line development market. The cell line development technology is used in manufacturing various vaccines in order to treat viral infection such as HIV, influenza, and more. These vaccines prove to stimulate body immune system. Besides this, cell line technology has successful manufactured vaccine which could treat mild or moderate coronavirus. For a novel monoclonal antibody to treat COVID-19 that prevents the activity of the omicron variant, the US Food and Drug Administration (FDA) granted an Emergency Use Authorization (EUA) in February 2022.
Growth Drivers
According to the International Osteoporosis Foundation, every year, osteoporosis causes more than 8.9 million fractures worldwide, culminating in an osteoporosis fracture every 3 seconds.
To deal with growing osteoporosis monoclonal antibodies are prepared which is known are stimulating antibodies in patient. Hence owing to this the market is expected to boost in the forecast period.
As of February 2022, there had been approximate 5 million confirmed deaths due to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) worldwide, which has caused over 400 million cases.
According to the World Health Organization, about 30% of cancer cases in low- and lower-middle-income nations are caused by cancer-causing diseases such the human papillomavirus (HPV) and hepatitis.
According to the European Academy of Neurology, over the past 30 years, the incidence of deaths from neurological disorders has climbed by approximately 40%, with 1 in 3 persons experiencing a neurological ailment at some point in their lives.
Mammalian cell culture has recently become essential to the biomanufacturing of viral vaccines and therapeutic proteins. Through viral infection, these cells create vaccines, and through genetic engineering, they produce therapeutic proteins.
Challenges
|
Base Year |
2023 |
|
Forecast Year |
2024-2036 |
|
CAGR |
10.1% |
|
Base Year Market Size (2023) |
USD 5.44 billion |
|
Forecast Year Market Size (2036) |
USD 19 billion |
|
Regional Scope |
|
The global cell line development market is segmented and analyzed for demand and supply by cell type into CHO cells, BHK 21 cells, NSO cells, murine C127 cells, NIH3T3 cells, L929 cells, and others. Out of which, BHK 21 cells segment is anticipated to garner the revenue share of 12.63% by the end of 2036, by growing at a highest CAGR of 12.84% during the forecast period. Increasing cases of rabies is expected to boost the market growth. BHK 21 cells are most frequently used cells lines. They are extensively used for treating rabies. The World Organization for Animal Health use these BHK21 cells in the regular diagnosis of rabies. To thrive in serum- or animal-component-free cell medium for the manufacture of rabies vaccines, BHK21 cells appear to have already undergone the necessary adaptations. Additionally CHO cells segment is anticipated to garner the largest revenue share of USD 27.89% by the end of 2036.
Our in-depth analysis of the global cell line development market includes the following segments:
|
By Product |
|
|
By Cell Type |
|
|
By Application |
|
|
By Industry |
|
Regionally, the global cell line development market is studied into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region. Amongst these markets, the market in Asia Pacific is projected to hold the market share of USD 3,945.1 Million by the end of 2031, up from a revenue of USD 1,166.9 Million in the year 2021. Further, the market in Asia Pacific is expected to grow at the highest CAGR of 13.02% over the forecast period.
Besides North America is set to hold highest industry share of 40% by 2036, backed by increasing investments and funds made available to manufacturing businesses and academic & research institutions to develop cell line-based end products like precision medicine and other treatments. In 2018, the National Institutes of Health's All of Us Research Program funded Genome Centers to generate genotype sequencing data from bio samples. To aid researchers in their quest to better understand how genetics, environment, and lifestyle choices affect health outcomes, they seek to create a varied network of more than 1 million participant partners across the US. In the upcoming years, it is anticipated that these factors will encourage market expansion.
Author Credits: Radhika Pawar
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?